MedTrace Logo

Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism

NCT00330434 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-11-10

No results posted yet for this study

Summary

The two purposes of this study are

1. to determine what effect the chronic and moderate/heavy drinking of alcoholic beverages has

1. on the blood level of bupropion and chlorzoxazone and their major breakdown products in the blood and
2. on the stimulant effect of bupropion and
2. to determine what effect a normal and common (25% frequency) genetic variation of a specific liver enzyme (that breaks down bupropion) has

1. on the blood levels of bupropion and its major breakdown products in the blood and
2. on the stimulant effect of bupropion.

Two groups of volunteers will be recruited for this study:

1. volunteers who drink moderate to heavy amounts of alcohol frequently and
2. volunteers who usually do not drink alcohol.

Volunteers will NOT be asked to change their drinking (or nondrinking) habits during the study.

Conditions

  • Alcohol Drinking
  • Depression
  • Smoking Cessation
  • Attention Deficit Disorder

Interventions

OTHER

Trial Withdrawn 1

Trial Withdrawn 1

OTHER

Trial Withdrawn 2

Trial Withdrawn 2

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • Tufts University

    lead OTHER

Principal Investigators

  • David J. Greenblatt, MD · Tufts University; Chair of Department of Pharmacology and Experimental Therapeutics, Sackler School

  • Michael H. Court, BVsc, PhD · Tufts University, Department of Pharmacology and Experimental Therapeutics, Sackler School

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00330434 on ClinicalTrials.gov